广生堂：公司GST-HG141的III期临床试验正在顺利推进，目前入组人数已过半

Group 1 - The company is progressing well with the Phase III clinical trial of its product GST-HG141, with more than half of the required participants already enrolled [1] - The overall progress of the trial is in line with expectations, and the research has been included in a national major science and technology project aimed at controlling new and major infectious diseases [1] - The company aims to leverage the resources and policy support from the national project to accelerate the development of GST-HG141, with the goal of obtaining market approval as soon as possible to benefit patients [1]